目的 探讨清肺抑火胶囊联合吸入用布地奈德混悬液治疗急性支气管炎的临床疗效。方法 选取2017年3月—2019年10月郑州大学第五附属医院收治的98例急性支气管炎患者，根据随机数字表法将患者分为对照组和治疗组，每组各49例。对照组雾化吸入吸入用布地奈德混悬液，将2 mL布地奈德加入0.9%氯化钠溶液3 mL，2次/d。治疗组在对照组基础上口服清肺抑火胶囊，4粒/次，2次/d。两组患者均连续治疗10 d。观察两组的临床疗效，比较两组临床症状、肺功能指标。结果 治疗后，治疗组总有效率为89.80%，高于对照组的65.31%（P<0.05）。治疗后，治疗组的体温恢复正常时间、咳嗽消失时间、啰音消失时间均短于对照组（P<0.05）。治疗后，两组患者第一秒用力呼气容积（FEV1）、用力肺活量（FVC）、呼气峰流速（PEF）占预计值百分比均升高（P<0.05），且治疗组肺功能指标高于对照组（P<0.05）。结论 清肺抑火胶囊联合吸入用布地奈德混悬液治疗急性支气管炎具有较好的临床疗效，可改善临床症状、肺功能，具有一定临床推广价值。

Objective To investigate the clinical effect of Qingfei Yihuo Capsules combined with budesonide in treatment of acute bronchitis. Methods Patients (98 cases) with acute bronchitis in the Fifth Affiliated Hospital of Zhengzhou University from March 2017 to October 2019 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were atomization inhalation administered with Budesonide Suspension for inhalation, 2 mL added into 0.9% sodium chloride solution 3 mL, after mixing evenly, twice daily. Patients in the treatment group were po administered with Qingfei Yihuo Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacies were evaluated, and clinical symptoms and pulmonary function indexes in two groups were compared. Results After treatment, the total clinical effective rate of the treatment group was 89.80%, which was higher than that of the control group (65.31%) (P<0.05). After treatment, the body temperature returned to normal time, cough disappeared time, and rales disappeared time in the treatment group were shorter than those in the control group (P<0.05). After treatment, FEV1, FVC, and percentage of PEF estimated value in the two groups were increased (P<0.05), and the pulmonary function index in the treatment group was higher than that in the control group (P<0.05). Conclusion Qingfei Yihuo Capsules combined with budesonide has clinical curative effect in treatment of acute bronchitis, can improve the clinical symptoms and lung function of patients, which is worthy of clinical promotion.

R974

河南省医学科技攻关计划项目（20160209）